

NEWS BRIEF

Provided by: Hausmann-Johnson Insurance | The Benefit Services Group, Inc.

CDC Study Finds Pfizer-BioNTech and Moderna Vaccines 90% Effective in Real-world Conditions

The Centers for Disease Control and Prevention (CDC) has released a [report](#) on the effectiveness of COVID-19 vaccines in real-world conditions. The study found the Pfizer-BioNTech and Moderna COVID-19 two-dose vaccines to be 90% effective at preventing infections two weeks after the second vaccine dose. Additionally, the study found the vaccines to be 80% effective at preventing infections two weeks after one dose.

The study was conducted on 3,950 health care personnel, first responders and other essential and frontline workers who completed weekly COVID-19 testing for 13 consecutive weeks.

The Pfizer-BioNTech and Moderna COVID-19 vaccines have been shown to be effective in preventing symptomatic cases of COVID-19 in clinical trials. However, according to the CDC, the benefits of these vaccines for preventing asymptomatic and symptomatic COVID-19 infections are less understood, particularly when administered in real-world conditions.

Because the study focused on analyzing the efficacy of COVID-19 vaccines on a group of front-line working adults whose jobs put them at a high risk of COVID-19 exposure, health experts view the CDC's report as significant. The findings from this report are largely consistent with clinical studies of the efficacy of COVID-19 vaccines. Importantly, the implications of this report displayed that COVID-19 vaccines are effective for preventing infection in real-world conditions.

Next Steps

The CDC continues to recommend COVID-19 vaccination for all eligible persons. The agency studies the efficacy of COVID-19 vaccines on an ongoing basis and issues new reports periodically.

Hausmann-Johnson Insurance | The Benefit Services Group, Inc. will keep you updated on any noteworthy developments.

Hausmann | Johnson
I N S U R A N C E

BSG THE
BENEFIT
SERVICES
GROUP, INC.

BSG
Analytics™ LLC